Disease Information
General Information of the Disease (ID: DIS00189)
Name |
Urinary tuberculosis
|
---|---|
ICD |
ICD-11: 1G80
|
Resistance Map |
Type(s) of Resistant Mechanism of This Disease
EADR: Epigenetic Alteration of DNA, RNA or Protein
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
Isoniazid
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Catalase-peroxidase (KATG) | [1] | |||
Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
Molecule Alteration | Missense mutation | p.S531L |
||
Resistant Drug | Isoniazid | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
Experiment for Molecule Alteration |
Gene sequencing assay | |||
Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
Key Molecule: DNA-directed RNA polymerase subunit beta (RPOB) | [1] | |||
Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
Molecule Alteration | Missense mutation | p.S531L |
||
Resistant Drug | Isoniazid | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
Experiment for Molecule Alteration |
Gene sequencing assay | |||
Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
Key Molecule: Catalase-peroxidase (KATG) | [1] | |||
Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
Molecule Alteration | Missense mutation | p.S315T1 |
||
Resistant Drug | Isoniazid | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
Experiment for Molecule Alteration |
Gene sequencing assay | |||
Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
Key Molecule: DNA-directed RNA polymerase subunit beta (RPOB) | [1] | |||
Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
Molecule Alteration | Missense mutation | p.S315T1 |
||
Resistant Drug | Isoniazid | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
Experiment for Molecule Alteration |
Gene sequencing assay | |||
Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. |
Rifampin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: DNA-directed RNA polymerase subunit beta (RPOB) | [1] | |||
Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
Molecule Alteration | Missense mutation | p.S531L |
||
Resistant Drug | Rifampin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
Experiment for Molecule Alteration |
Gene sequencing assay | |||
Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
Key Molecule: DNA-directed RNA polymerase subunit beta (RPOB) | [1] | |||
Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
Molecule Alteration | Missense mutation | p.S315T1 |
||
Resistant Drug | Rifampin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
Experiment for Molecule Alteration |
Gene sequencing assay | |||
Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Catalase-peroxidase (KATG) | [1] | |||
Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
Molecule Alteration | Missense mutation | p.S531L |
||
Resistant Drug | Rifampin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
Experiment for Molecule Alteration |
Gene sequencing assay | |||
Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. | |||
Key Molecule: Catalase-peroxidase (KATG) | [1] | |||
Resistant Disease | Urinary tuberculosis [ICD-11: 1G80.0] | |||
Molecule Alteration | Missense mutation | p.S315T1 |
||
Resistant Drug | Rifampin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis isolates | 1773 | ||
Experiment for Molecule Alteration |
Gene sequencing assay | |||
Mechanism Description | Regarding drug-resistance mutation profiles, the most prevalent mutation sites were katG S315T1 and rpoB S531L. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.